These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 21057566)

  • 21. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
    Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
    Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Non-muscle-invasive transitional cell carcinoma. Is BCG still a necessary part of treatment?].
    vom Dorp F; Tschirdewahn S; Rübben H; Jocham D
    Urologe A; 2010 Oct; 49(10):1274-6. PubMed ID: 20938822
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prospective phase II trial of alternating intravesical Bacillus Calmette-Guérin (BCG) and interferon alpha IIB in the treatment and prevention of superficial transitional cell carcinoma of the urinary bladder: preliminary results.
    Bazarbashi S; Raja MA; El Sayed A; Ezzat A; Ibrahim E; Kattan S; Kardar A; Peracha A; Lindstedt E; Hanash K
    J Surg Oncol; 2000 Jul; 74(3):181-4. PubMed ID: 10951412
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
    Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
    Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term follow-up of intravesical bacillus Calmette-Guérin treatment for superficial transitional-cell carcinoma of the bladder involving the prostatic urethra.
    Taylor JH; Davis J; Schellhammer P
    Clin Genitourin Cancer; 2007 Sep; 5(6):386-9. PubMed ID: 17956711
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.
    Oddens JR; Sylvester RJ; Brausi MA; Kirkels WJ; van de Beek C; van Andel G; de Reijke TM; Prescott S; Witjes JA; Oosterlinck W
    Eur Urol; 2014 Oct; 66(4):694-701. PubMed ID: 24948466
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Single monthly bacillus Calmette-Guérin intravesical instillation is effective maintenance therapy to prevent recurrence in Japanese patients with non-muscle-invasive bladder cancer.
    Okamura T; Akita H; Ando R; Ikegami Y; Naiki T; Kawai N; Tozawa K; Kohri K
    Int J Clin Oncol; 2012 Oct; 17(5):477-81. PubMed ID: 21947596
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recurrence and progression of T1G3 transitional cell carcinoma of the bladder treated with intravesical bacillus Calmette-Guérin.
    Günlüsoy B; Değirmenci T; Arslan M; Nergiz N; Minareci S; Ayder AR
    Urol Int; 2005; 75(2):107-13. PubMed ID: 16123562
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intra-arterial chemotherapy combined with intravesical chemotherapy compared with intravesical BCG immunotherapy retrospectively in high-risk non-muscle-invasive bladder cancer after transurethral resection of the bladder tumor.
    Huang B; Huang G; Li W; Chen L; Mao X; Chen J
    J Cancer Res Clin Oncol; 2021 Jun; 147(6):1781-1788. PubMed ID: 33222014
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravesical 4'-epi-doxorubicin (epirubicin) versus bacillus Calmette-Guérin. A controlled prospective study on the prophylaxis of superficial bladder cancer.
    Melekos MD; Chionis HS; Paranychianakis GS; Dauaher HH
    Cancer; 1993 Sep; 72(5):1749-55. PubMed ID: 8348504
    [TBL] [Abstract][Full Text] [Related]  

  • 31. T1G3 transitional cell carcinoma of the bladder: recurrence, progression and survival.
    Peyromaure M; Zerbib M
    BJU Int; 2004 Jan; 93(1):60-3. PubMed ID: 14678369
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
    Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
    J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial.
    Divrik RT; Yildirim U; Zorlu F; Ozen H
    J Urol; 2006 May; 175(5):1641-4. PubMed ID: 16600720
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer.
    Librenjak D; Situm M; Eterovic D; Dogas Z; Gotovac J
    Croat Med J; 2003 Apr; 44(2):187-92. PubMed ID: 12698510
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Intravesical adjuvant chemotherapy for superficial bladder cancer -- results of a survey in Saxony].
    Steinbach F; Schuster F
    Aktuelle Urol; 2005 Aug; 36(4):337-41. PubMed ID: 16110407
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intravesical instillation of bacille Calmette-Guérin for superficial bladder cancer: cost-effectiveness analysis.
    Uchida A; Yonou H; Hayashi E; Iha K; Oda M; Miyazato M; Oshiro Y; Hokama S; Sugaya K; Ogawa Y
    Urology; 2007 Feb; 69(2):275-9. PubMed ID: 17320663
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Retrospective analysis of transurethral resection, second-look resection, and long-term chemo-metaphylaxis for superficial bladder cancer: indications and efficacy of a differentiated approach.
    Schulze M; Stotz N; Rassweiler J
    J Endourol; 2007 Dec; 21(12):1533-41. PubMed ID: 18186695
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Results of conservative treatment (transurethral resection plus adjuvant intravesical chemotherapy) in patients with primary T1, G3 transitional cell carcinoma of the bladder.
    Serretta V; Piazza S; Pavone C; Piazza B; Pavone-Macaluso M
    Urology; 1996 May; 47(5):647-51. PubMed ID: 8650860
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term results of intravesical bacillus Calmette-Guérin therapy for stage T1 superficial bladder cancer.
    Brake M; Loertzer H; Horsch R; Keller H
    Urology; 2000 May; 55(5):673-8. PubMed ID: 10792077
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The ablative effect of quarter dose bacillus Calmette-Guerin on a papillary marker lesion of the bladder.
    Mack D; Höltl W; Bassi P; Brausi M; Ferrari P; de Balincourt C; Sylvester R;
    J Urol; 2001 Feb; 165(2):401-3. PubMed ID: 11176382
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.